Karyopharm Therapeutics (KPTI) Earns Media Sentiment Rating of 0.10

Media coverage about Karyopharm Therapeutics (NASDAQ:KPTI) has trended somewhat positive this week, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.10 on Alpha One’s scale. Alpha One also gave news articles about the company an impact score of 74 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have effected Alpha One Sentiment’s analysis:

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 1.53% on Friday, reaching $9.95. 173,554 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The stock’s market capitalization is $468.82 million. The company has a 50 day moving average of $10.61 and a 200-day moving average of $10.14.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.04. The business had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.02 million. During the same period last year, the firm posted ($0.75) EPS. Equities research analysts forecast that Karyopharm Therapeutics will post ($2.68) earnings per share for the current year.

KPTI has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $14.00 price objective (down from $15.00) on shares of Karyopharm Therapeutics in a research report on Tuesday, March 7th. Canaccord Genuity reissued a “buy” rating and set a $20.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday, March 13th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 21st. Wedbush reissued an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a research report on Saturday, March 4th. Finally, Robert W. Baird reissued an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, April 6th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $14.32.

WARNING: This report was originally posted by Mideast Time and is owned by of Mideast Time. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.mideasttime.com/karyopharm-therapeutics-kpti-earns-media-sentiment-rating-of-0-10/1708460.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

5 Day Chart for NASDAQ:KPTI

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.